Wedbush Maintains Outperform on BioCryst Pharma, Lowers Price Target to $17
Benzinga Newsdesk 5 hours ago
Analyst RatingsNewsPrice Target
Wedbush analyst Laura Chico maintains BioCryst Pharma (NASDAQ:BCRX) with a Outperform and lowers the price target from $18 to $17.
Wedbush analyst Laura Chico maintains BioCryst Pharma (NASDAQ:BCRX) with a Outperform and lowers the price target from $18 to $17.